Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 14/20 | 0.45 |
| ▸ | TACR1 | P25103 | 6/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3764734 | 1.00 | TACR2 (0.45) | TACR2TACR1CYP3A4SIGMAR1 | |
| Fumaric Acid SCHEMBL4745570 | 0.96 | TACR2 (0.44) | TACR2TACR1CYP3A4SIGMAR1 | |
| Maleic Acid SCHEMBL4748529 | 0.96 | TACR2 (0.44) | TACR2TACR1CYP3A4SIGMAR1 | |
| Fumaric Acid SCHEMBL4745568 | 0.96 | TACR2 (0.44) | TACR2TACR1CYP3A4SIGMAR1 | |
| SCHEMBL3761709 | 0.93 | TACR2 (0.45) | TACR2TACR1 | |
| SCHEMBL3771236 | 0.92 | TACR2 (0.44) | TACR2TACR1 | |
| SCHEMBL3766893 | 0.92 | TACR2 (0.44) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL3773045 | 0.92 | TACR2 (0.44) | TACR2TACR1 | |
| SCHEMBL3779290 | 0.92 | TACR2 (0.44) | TACR2TACR1 | |
| Hydrochloric Acid SCHEMBL3776356 | 0.92 | TACR2 (0.44) | TACR2TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940845-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | claimed |
| WO-2007037743-A1 | NOVEL AZETIDINE COMPOUNDS USEFUL IN THE TREATMENT OF FUNCTIONAL GASTROINTESTINAL DISORDERS, IBS AND FUNCTIONAL DYSPEPSIA | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | WO | claimed |